European Phase IIb Trial in Type 1 Diabetes With the Diabetes Vaccine Diamyd® Close to Being Fully Recruited

STOCKHOLM, March 8, 2019 /PRNewswire/ — 91 out of a total of 106 patienter with type 1 diabetes are included in the European phase IIb trial DIAGNODE-2, where the diabetes vaccine Diamyd® is given directly into the lymph node with the aim to preserve the patients’ endogenous insulin production. As previously announced, results from the trial are expected during the third quarter of 2020.

The Phase IIb trial DIAGNODE-2 is a follow up trial based on a smaller investigator initiated pilot trial, DIAGNODE-1, where results show that 11 out of 12 patients recently diagnosed with type 1 diabetes are in a so called honeymoon period, also called partial remission, 15 months after the start of the trial. Partial remission in type 1 diabetes is characterized by low external insulin requirement and near to normal long-term blood sugar levels. The results also show effect on preserving the patients’ endogenous insulin production, measured as stimulated C-peptid. By maintaining the endogenous insulin production there is a potential to make a significant difference in the daily life of patients as well as to reduce the complications of type 1 diabetes..

For more click –>

Print Friendly, PDF & Email